Prevention and management of prostate cancer chemotherapy complications

Urologic Clinics of North America

Volumn 31, Issue 2, 2004, Pages 367-378

  Beer, Tomasz M ^a   Bubalo, Joseph S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CALCIUM; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE SODIUM; ETOPOSIDE; GROWTH FACTOR; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LOPERAMIDE; MITOXANTRONE; NAVELBINE; NEUROKININ 1 RECEPTOR ANTAGONIST; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PHENOBARBITAL; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; UNINDEXED DRUG; VINBLASTINE; WARFARIN;

ACNE; ACUPRESSURE; ACUPUNCTURE; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; APPETITE DISORDER; ARTHRALGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRADYCARDIA; BREAST TENDERNESS; BRONCHOSPASM; CATARACT; CHEMOTHERAPY INDUCED EMESIS; CONJUNCTIVITIS; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DYSPNEA; EDEMA; ESOPHAGITIS; EXTRAVASATION; FEBRILE NEUTROPENIA; FEVER; FLATULENCE; FLUID RETENTION; FLUSHING; GLAUCOMA; GYNECOMASTIA; HAIR LOSS; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEMORRHAGIC COLITIS; HEMORRHAGIC CYSTITIS; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INDIGESTION; INFERTILITY; JAUNDICE; LEG CRAMP; LETHARGY; LEUKOPENIA; LIBIDO DISORDER; LIVER DYSFUNCTION; LUNG EMBOLISM; MALAISE; MALE; MOOD DISORDER; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; NERVOUSNESS; NEUROPATHY; NEUTROPENIA; NIGHT SWEAT; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; PSYCHOSIS; RASH; RAYNAUD PHENOMENON; REVIEW; SKIN EXFOLIATION; STOMATITIS; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; TINNITUS; TREATMENT OUTCOME; URINE RETENTION; VERTIGO;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2342447342     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2004.01.003     Document Type: Review

References (84)

1. Gilligan T., Kantoff P.W. Chemotherapy for prostate cancer. Urology. 60:(3 Suppl 1):2002;94-100. [discussion]
2. Petrylak D.P. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol. 20:(3 Suppl 1):2002;31-35
3. Madalinska J.B., Essink-Bot M.L., de Koning H.J., Kirkels W.J., van der Maas P.J., Schroder F.H. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 19:(6):2001;1619-1628
4. Diamond T., Campbell J., Bryant C., Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 83:(8):1998;1561-1566
5. Hatano T., Oishi Y., Furuta A., Iwamuro S., Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 86:(4):2000;449-452
6. National Cancer Institute. Cancer Therapy Evaluation Program information. Available at: http://ctep.info.nih.gov. Accessed February 9, 2004.
7. Hudes G., Einhorn L., Ross E., Balsham A., Loehrer P., Ramsey H., et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 17:(10):1999;3160-3166
8. Hoekman K., van der Vijgh W.J., Vermorken J.B. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Drugs. 57:(2):1999;133-155
9. Wilkes J.D. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol. 25:(5):1998;538-551
10. Diemunsch P., Grelot L. Potential of substance P antagonists as antiemetics. Drugs. 60:(3):2000;533-546
11. Gralla R.J., Osoba D., Kris M.G., Kirkbride P., Hesketh P.J., Chinnery L.W., et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 17:(9):1999;2971-2994
12. Therapeutic A.S.H.P. Guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 56:(8):1999;729-764
13. Hesketh P.J. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 4:(3):1999;191-196
14. Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol. 249:(1):2002;9-17
15. Gogas H., Shapiro F., Aghajanian C., Fennelly D., Almadrones L., Hoskins W.J., et al. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol. 61:(1):1996;22-26
16. Mauch P., Constine L., Greenberger J., Knospe W., Sullivan J., Liesveld J.L., et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 31:(5):1995;1319-1339
17. Serafini A.N. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer. 88:(12 Suppl):2000;2934-2939
18. Friedland J. Local and systemic radiation for palliation of metastatic disease. Urol Clin North Am. 26:(2):1999;391-402
19. Lichtman S.M., Skirvin J.A. Pharmacology of antineoplastic agents in older cancer patients. Oncology (Huntingt). 14:(12):2000;1743-1755
20. Bicher A., Sarosy G., Kohn E., Adamo D.O., Davis P., Jacob J., et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer. 71:(2 Suppl):1993;594-600
21. Berry W., Beer T.M. Efficacy and toxicity of weekly docetaxel in the elderly, a pooled comparison of outcome in men with androgen independent prostate cancer (AIPC) > 70 vs<70 years of age. Proc Am Soc Clin Oncol. 22:2003;745
22. Lancet J.E., Willman C.L., Bennett J.M. Acute myelogenous leukemia and aging. Clinical interactions. Hematol Oncol Clin North Am. 14:(1):2000;251-267
23. Niitsu N. Non-Hodgkin's lymphoma in the elderly: a guide to drug treatment. Drugs Aging. 14:(6):1999;447-457
24. Wilking N. Chemotherapy in the elderly. Eur J Surg Oncol. 24:(5):1998;412-417
25. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 5:(3):2000;224-237
26. Innocenti F., Iyer L., Ratain M.J. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 39:(5):2000;315-325
27. Rioux P.P. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health Syst Pharm. 57:(9):2000;887-898
28. Innocenti F., Iyer L., Ratain M.J. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos. 29:(4 Pt 2):2001;596-600
29. Nagasubramanian R., Innocenti F., Ratain M.J. Pharmacogenetics in cancer treatment. Annu Rev Med. 54:2003;437-452
30. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 14:(6):1996;1756-1764
31. Kantoff P.W., Halabi S., Conaway M., Picus J., Kirshner J., Hars V., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 17:(8):1999;2506-2513
32. Lacy C., Armstrong L., Goldman M., Lance L. Drug information handbook. 1999;Lexi-Comp Inc. Hudson (Ohio)
33. Picus J., Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 26:(5 Suppl 17):1999;14-18
34. Friedland D., Cohen J., Miller R. Jr., Voloshin M., Gluckman R., Lembersky B., et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol. 26:(5 Suppl 17):1999;19-23
35. Beer T.M., Pierce W.C., Lowe B.A., Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 12:(9):2001;1273-1279
36. Berry W., Dakhil S., Gregurich M.A., Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 28:(4 Suppl 15):2001;8-15
37. Savarese D.M., Halabi S., Hars V., Akerley W.L., Taplin M.E., Godley P.A., et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 19:(9):2001;2509-2516
38. Sinibaldi V.J., Carducci M.A., Moore-Cooper S., Laufer M., Zahurak M., Eisenberger M.A. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 94:(5):2002;1457-1465
39. Copur M.S., Ledakis P., Lynch J., Hauke R., Tarantolo S., Bolton M., et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol. 28:(4 Suppl 15):2001;16-21
40. Hudes G.R., Nathan F., Khater C., Haas N., Cornfield M., Giantonio B., et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 15:(9):1997;3156-3163
41. Ferrari A.C., Chachoua A., Singh H., Rosenthal M., Taneja S., Bednar M., et al. A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Cancer. 91:(11):2001;2039-2045
42. Vaishampayan U., Fontana J., Du W., Hussain M. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology. 60:(6):2002;1050-1054
43. Pienta K.J., Redman B., Hussain M., Cummings G., Esper P.S., Appel C., et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 12:(10):1994;2005-2012
44. Pienta K.J., Redman B.G., Bandekar R., Strawderman M., Cease K., Esper P.S., et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology. 50:(3):1997;401-406
45. Dimopoulos M.A., Panopoulos C., Bamia C., Deliveliotis C., Alivizatos G., Pantazopoulos D., et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology. 50:(5):1997;754-758
46. Smith D.C., Esper P., Strawderman M., Redman B., Pienta K.J. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol. 17:(6):1999;1664-1671
47. Kelly W.K., Curley T., Slovin S., Heller G., McCaffrey J., Bajorin D., et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 19:(1):2001;44-53
48. Ellerhorst J.A., Tu S.M., Amato R.J., Finn L., Millikan R.E., Pagliaro L.C., et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 3:(12 Pt 1):1997;2371-2376
49. Balducci L., Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer. 80:(7):1997;1317-1322
50. Vestal R.E., Calabresi P. Geriatric clinical pharmacologist and medical oncologist: a new partnership? Clin Pharmacol Ther. 62:(4):1997;361-364
51. LeSage J. Polypharmacy in geriatric patients. Nurs Clin North Am. 26:(2):1991;273-290
52. Markowitz J.O., Donovan J.L., DeVane C.L., Taylor R.M., et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 290:(11):2003;1500-1504
53. Raucy J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos. 31:(5):2003;533-539
54. Ruschitzka F., Meier P.J., Turina M., Luscher T.F., Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet. 355:(9203):2000;548-549
55. Johne A., Brockmoller J., Bauer S., Maurer A., Langheinrich M., Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther. 66:(4):1999;338-345
56. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 38:(1):2000;41-57
57. Johnston E.M., Crawford J. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Semin Oncol. 25:(5):1998;552-561
58. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 18:(20):2000;3558-3585
59. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., Einhorn L.H. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 19:(11):2001;2875-2882
60. Demetri G.D., Kris M., Wade J., Degos L., Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 16:(10):1998;3412-3425
61. Glaspy J.A., Tchekmedyian N.S. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Huntingt). 16:(10 Suppl 11):2002;23-29
62. Glaspy J.A., Jadeja J.S., Justice G., Fleishman A., Rossi G., Colowick A.B. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 97:(5):2003;1312-1320
63. Dodd M.J., Larson P.J., Dibble S.L., Miaskowski C., Greenspan D., MacPhail L., et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum. 23:(6):1996;921-927
64. Meropol N.J., Somer R.A., Gutheil J., Pelley R.J., Modiano M.R., Rowinsky E.K., et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 21:(8):2003;1452-1458
65. Fauser A.A., Fellhauer M., Hoffmann M., Link H., Schlimok G., Gralla R.J. Guidelines for anti-emetic therapy: acute emesis. Eur J Cancer. 35:(3):1999;361-370
66. Hesketh P.J., Van Belle S., Aapro M., Tattersall F.D., Naylor R.J., Hargreaves R., et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 39:(8):2003;1074-1080
67. Hesketh P.J. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer. 9:(5):2001;350-354
68. Koeller J.M., Aapro M.S., Gralla R.J., Grunberg S.M., Hesketh P.J., Kris M.G., et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer. 10:(7):2002;519-522
69. Aloxi. 2003;Pharma MGI, Bloomington (Minnesota). [prescribing information]
70. Aprepitant. 2003;Merck & Co. Whitehouse Station (New Jersey). [prescribing information]
71. Markman M. What primary care physicians should know about the toxicity of cancer chemotherapy. Cleve Clin J Med. 64:(6):1997;331-333
72. Roscoe J.A., Morrow G.R., Bushunow P., Tian L., Matteson S. Acustimulation wristbands for the relief of chemotherapy-induced nausea. Altern Ther Health Med. 8:(4):2002;56-57
73. Roscoe J.A., Morrow G.R., Hickok J.T., Bushunow P., Pierce H.I., Flynn P.J., et al. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. J Pain Symptom Manage. 26:(2):2003;731-742
74. Shen J., Wenger N., Glaspy J., Hays R.D., Albert P.S., Choi C., et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: a randomized controlled trial. JAMA. 284:(21):2000;2755-2761
75. Johnstone P.A., Polston G.R., Niemtzow R.C., Martin P.J. Integration of acupuncture into the oncology clinic. Palliat Med. 16:(3):2002;235-239
76. Garrison J.A., McCune J.S., Livingston R.B., Linden H.M., Gralow J.R., Ellis G.K., et al. Myalgias and arthralgias associated with paclitaxel. Oncology (Huntingt). 17:(2):2003;271-277
77. Savarese D., Boucher J., Corey B. Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J Clin Oncol. 16:(12):1998;3918- 3919
78. Biswal B.M., Zakaria A., Ahmad N.M. Topical application of honey in the management of radiation mucositis: a preliminary study. Support Care Cancer. 11:(4):2003;242-248
79. Lacy C., Armstrong L., Goldman M., Lance L. Drug information handbook. 2002;Lexi-Comp Inc. Hudson (Ohio)
80. Skirvin J.A., Lichtman S.M. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging. 19:(1):2002;25-42
81. Lam M.S.H., Ignoffo R.J. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Practice. 9:(2-3):2003;45-85
82. Moosa A., Dobish R., Watts C. Interacting with drugs used in oncology: an Alberta Cancer Board Initiative. J Oncol Pharm Practice. 9:(2-3):2003;87-107
83. Horowitz B.Z., Bizovi K., Moreno R. Droperidol-behind the black box warning. Acad Emerg Med. 9:(6):2002;615-618
84. Habib A.S., Gan T.J. Food and drug administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg. 96:(5):2003;1377-1379